De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?
De novo metastatic hormone-sensitive PC (mHSPC) accounts for 5–10% of all prostate cancer (PC) diagnoses but it is responsible for nearly 50% of PC-related deaths. Since 2015, the prognosis of mHSPC has slightly improved thanks to the introduction of new hormonal agents and chemotherapy combined wit...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/20/4945 |
| _version_ | 1797574360287936512 |
|---|---|
| author | Claudia Piombino Marco Oltrecolli Elena Tonni Marta Pirola Rossana Matranga Cinza Baldessari Stefania Pipitone Massimo Dominici Roberto Sabbatini Maria Giuseppa Vitale |
| author_facet | Claudia Piombino Marco Oltrecolli Elena Tonni Marta Pirola Rossana Matranga Cinza Baldessari Stefania Pipitone Massimo Dominici Roberto Sabbatini Maria Giuseppa Vitale |
| author_sort | Claudia Piombino |
| collection | DOAJ |
| description | De novo metastatic hormone-sensitive PC (mHSPC) accounts for 5–10% of all prostate cancer (PC) diagnoses but it is responsible for nearly 50% of PC-related deaths. Since 2015, the prognosis of mHSPC has slightly improved thanks to the introduction of new hormonal agents and chemotherapy combined with androgen deprivation therapy from the first-line setting. This review describes the current therapeutic opportunities for de novo mHSPC, focusing on potential molecular biomarkers identified in the main clinical trials that have modified the standard of care, the genomic features of de novo mHSPC, and the principal ongoing trials that are investigating new therapeutic approaches and the efficacy of a biomarker-guided treatment in this setting. The road toward personalized treatment for de novo mHSPC is still long, considering that the randomized clinical trials, which have furnished the basis of the current therapeutic options, stratified patients according to clinical criteria that did not necessarily reflect the biological rationale of the chosen therapy. The role of transcriptomic profiling of mHSPC as a predictive biomarker requires further validation, and it remains to be ascertained how the genomic variants detected in mHSPC, which are regarded as predictive in the castration-resistant disease, can be exploited in the mHSPC setting. |
| first_indexed | 2024-03-10T21:22:50Z |
| format | Article |
| id | doaj.art-b249130b8e9d487eb8b94a12d82c66a9 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T21:22:50Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-b249130b8e9d487eb8b94a12d82c66a92023-11-19T15:58:21ZengMDPI AGCancers2072-66942023-10-011520494510.3390/cancers15204945De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?Claudia Piombino0Marco Oltrecolli1Elena Tonni2Marta Pirola3Rossana Matranga4Cinza Baldessari5Stefania Pipitone6Massimo Dominici7Roberto Sabbatini8Maria Giuseppa Vitale9Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, ItalyDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, ItalyDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, ItalyDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, ItalyDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, ItalyDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, ItalyDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, ItalyDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, ItalyDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, ItalyDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, ItalyDe novo metastatic hormone-sensitive PC (mHSPC) accounts for 5–10% of all prostate cancer (PC) diagnoses but it is responsible for nearly 50% of PC-related deaths. Since 2015, the prognosis of mHSPC has slightly improved thanks to the introduction of new hormonal agents and chemotherapy combined with androgen deprivation therapy from the first-line setting. This review describes the current therapeutic opportunities for de novo mHSPC, focusing on potential molecular biomarkers identified in the main clinical trials that have modified the standard of care, the genomic features of de novo mHSPC, and the principal ongoing trials that are investigating new therapeutic approaches and the efficacy of a biomarker-guided treatment in this setting. The road toward personalized treatment for de novo mHSPC is still long, considering that the randomized clinical trials, which have furnished the basis of the current therapeutic options, stratified patients according to clinical criteria that did not necessarily reflect the biological rationale of the chosen therapy. The role of transcriptomic profiling of mHSPC as a predictive biomarker requires further validation, and it remains to be ascertained how the genomic variants detected in mHSPC, which are regarded as predictive in the castration-resistant disease, can be exploited in the mHSPC setting.https://www.mdpi.com/2072-6694/15/20/4945metastatic hormone-sensitive prostate cancernew hormonal agentstranscriptomic profilingDNA damage repair genestumor suppressor genesandrogen receptor |
| spellingShingle | Claudia Piombino Marco Oltrecolli Elena Tonni Marta Pirola Rossana Matranga Cinza Baldessari Stefania Pipitone Massimo Dominici Roberto Sabbatini Maria Giuseppa Vitale De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment? Cancers metastatic hormone-sensitive prostate cancer new hormonal agents transcriptomic profiling DNA damage repair genes tumor suppressor genes androgen receptor |
| title | De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment? |
| title_full | De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment? |
| title_fullStr | De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment? |
| title_full_unstemmed | De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment? |
| title_short | De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment? |
| title_sort | de novo metastatic prostate cancer are we moving toward a personalized treatment |
| topic | metastatic hormone-sensitive prostate cancer new hormonal agents transcriptomic profiling DNA damage repair genes tumor suppressor genes androgen receptor |
| url | https://www.mdpi.com/2072-6694/15/20/4945 |
| work_keys_str_mv | AT claudiapiombino denovometastaticprostatecancerarewemovingtowardapersonalizedtreatment AT marcooltrecolli denovometastaticprostatecancerarewemovingtowardapersonalizedtreatment AT elenatonni denovometastaticprostatecancerarewemovingtowardapersonalizedtreatment AT martapirola denovometastaticprostatecancerarewemovingtowardapersonalizedtreatment AT rossanamatranga denovometastaticprostatecancerarewemovingtowardapersonalizedtreatment AT cinzabaldessari denovometastaticprostatecancerarewemovingtowardapersonalizedtreatment AT stefaniapipitone denovometastaticprostatecancerarewemovingtowardapersonalizedtreatment AT massimodominici denovometastaticprostatecancerarewemovingtowardapersonalizedtreatment AT robertosabbatini denovometastaticprostatecancerarewemovingtowardapersonalizedtreatment AT mariagiuseppavitale denovometastaticprostatecancerarewemovingtowardapersonalizedtreatment |